Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer by Maria Elena Lacruz, Saskia Thies, Andrea Schmidt-Pokrzywniak, Ian Wittenberg, Tobias Engler, Fabian Reinwald, Monika Klinkhammer-Schalke, Sylke Ruth Zeissig, Bianca Franke, Kerstin Weitmann, Atanas Ignatov

“…HER2-positive showed worse MFS, RFS, and OS than HER2-zero and HER2-low subtypes. …”
Get full text

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab t... by Huanhuan Li, Chao Ren, Donghai Cui, Tao Wu, Zhiyong Nie

“…Hence, it is a novel, highly specific, and potent therapeutic option for HER-2-positive patients and should henceforth be considered as a new treatment approach.…”
Get full text

HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients by Boqiang Lyu, Shidi Zhao, Hui Wang, Shouping Gong, Biyuan Wang

“…The prevalence of HER2 positive MBC fluctuated widely from 2001 to 2015 and then stabilized at 10%. …”
Get full text

A Cost-Effective and Robust Cell-Based Bioassay Method for Evaluating the Bioactivity of Trastuzumab-like Antibodies by Pooja Bharali, Subhash Chand, Harish Chander

“…<b>Background/Objectives:</b> Trastuzumab is an effective therapeutic intervention for treating HER2-positive breast cancers. The cost-effectiveness, global demand, and patent expiration of trastuzumab have led to the inflow of its biosimilars in the global market. …”
Get full text

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer by Riqing Huang, Anqi Hu, Qixiang Rong, Ditian Shu, Meiting Chen, Wei Yang, Yue Zhang, Qiufan Zheng, Xin An, Cong Xue, Haifeng Li, Yanxia Shi

“…ERBB2/CDK12 co-amplification may be a potential biomarker for favorable responses in HER2-positive breast cancer.…”
Get full text

The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy by Huihui Guo, Hongsheng Xie, Yuanyuan Huang, Junxiang Jia, Xiangfei Kong, Qingliang Yang, Shun Gai, Wenjun Li, Lu Bai, Lingli Zhang, Xiaoxiao Chen, Zhicang Ye, Hangbo Ye, Linyao Zhao, Yifang Xu, Yong Du, Xiuzhen Zhang, Miaomiao Chen, Xiaomai Zhou, Robert Y. Zhao

“…In vivo efficacy was assessed using three HER2-positive tumor models, with dose-dependent tumor growth inhibition compared to established treatments. …”
Get full text

Prognosis and cardiotoxicity associated to adjuvant trastuzumab for breast cancer: real world study in a public health system by Ana Elisa Ribeiro da Silva Cabello, César Cabello, Susana Oliveira Botelho Ramalho, Otávio Rizzi Coelho, Otávio Rizzi Coelho-Filho, Helymar da Costa Machado, Délio Marques Conde, Luiz Carlos Zeferino

“…Methods: This was a retrospective cohort study that included 255 HER2-positive breast cancer patients who received adjuvant trastuzumab therapy. …”
Get full text

Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature by Cristina Dumitrescu, Dominique Lossignol

“…We reviewed the pertinent literature and concluded that IT trastuzumab might be a promising treatment for patients with HER2-positive breast cancer leptomeningeal carcinomatosis.…”
Get full text

The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified... by Sanaa Gamrani, Laila Akhouayri, Sara Boukansa, Mehdi Karkouri, Hinde El Fatemi

“…There has been increased interest in HER2-low breast tumors recently, as these tumors may have distinct clinical and molecular characteristics compared to HER2-negative and HER2-positive tumors. A new nomenclature has been proposed for HER2 1+ and HER2 2+ tumors that are confirmed negative according to fluorescence in situ hybridization (FISH). …”
Get full text

Predictive factors for axillary pathological complete response to neoadjuvant therapy in elderly breast cancer patients by Yuying Wang, Rui Wang, Di Lu, Yaling Zeng, Xihui Tu, Shiwei Liu, Purong Zhang

“…Multivariate analysis revealed that apCR exhibited a significant association with initial cN0 stage and HER2 positivity. The apCR rate for HER2-positive elderly patients with initial cN0 disease is 100.0%,whereas the lowest apCR rate is observed in HER2-negative and clinical lymph nodes positive(cN+) patients(36.0%). …”
Get full text

Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments by Amit Verma, Vikas Pandey, Catherine Sherry, Taylor Humphrey, Christopher James, Kailie Matteson, Jason T. Smith, Alena Rudkouskaya, Xavier Intes, Margarida Barroso

“…NIR FLI FRET in vitro microscopy data show variations in intracellular distribution of bound TZM in HER2‐positive breast AU565 and AU565 tumor‐passaged XTM cell lines in comparison to SKOV‐3 ovarian cancer cells. …”
Get full text

Who Are Suitable Patients for Omitting Breast Surgery as an Exceptional Responder in Selected Molecular Subtypes of Breast Cancer After Neoadjuvant Systemic Treatment? by Ebru Sen, Mehmet Ali Nazlı, Göktürk Maralcan, Bekir Sıtkı Said Ulusoy, Mahmut Kaan Demircioğlu, Tuce Söylemez Akkurt, Mehmet Sökücü, Gökmen Umut Erdem, Mustafa Yıldırım

“…The patients with TN or HER2 positive breast cancer whose breast tumour had completely disappeared on the radiological assessment including MRI after neoadjuvant therapy were enrolled. …”
Get full text

Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation by Esin Oktay, Özlem Yersal, Nezih Meydan, Mehmet Sağıroğlu, Ömer Uyanık, Sabri Barutca

“…Combination therapy of lapatinib and capecitabine may be an effective treatment option for brain metastasis of HER2-positive breast cancer. We report a patient with breast cancer overexpressing HER-2 where brain metastases were successfully treated with radiation and a combination of lapatinib and capecitabine.…”
Get full text

Deep Seated Lobular Capillary Hemangioma (Pyogenic Granuloma) of the Colon: A Rare Case Requiring Surgery beyond Endoscopic Management by Jaechun Park, Minjung Jung

“…A 41-year-old woman presented with an incidental colonic mass during a systemic workup after adjuvant chemotherapy for HER2-positive breast cancer. Abdominal computed tomography revealed a deep seated colonic mass in the splenic flexure. …”
Get full text

New Antibody Conjugates in Cancer Therapy by Serengulam V. Govindan, David M. Goldenberg

“…The area of drug-conjugated antibodies is progressing with encouraging data published for the trastuzumab-DM1 conjugate in a phase I clinical trial in HER2-positive breast cancer. The Dock-and-Lock platform technology has contributed to the design and the evaluation of complex antibody-cytokine and antibody-toxin conjugates. …”
Get full text

Machine learning for predicting neoadjuvant chemotherapy effectiveness using ultrasound radiomics features and routine clinical data of patients with breast cancer by Pu Zhou, Pu Zhou, Hongyan Qian, Pengfei Zhu, Jiangyuan Ben, Jiangyuan Ben, Guifang Chen, Qiuyi Chen, Lingli Chen, Jia Chen, Ying He, Ying He

“…SHAP analysis provided a clear explanation for the prediction results of the GBM model, revealing that patients with a high Rad score, PR-negative status, ER-negative status and HER-2-positive status are more likely to achieve pCR.…”
Get full text

A HER2 Specific Nanobody–Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models by Anders H. Hansen, Kasper I. H. Andersen, Li Xin, Oliver Krigslund, Niels Behrendt, Lars H. Engelholm, Claus H. Bang-Bertelsen, Sanne Schoffelen, Katrine Qvortrup

“…Subsequent site-selective acylation on the C-terminally activated lysine residue allowed installation of the cytotoxin monomethyl auristatin E-functionalized cathepsin B-sensitive payload to provide a highly homogenous nanobody–drug conjugate (NBC), which demonstrated high potency and selectivity for HER2-positive breast cancer models.…”
Get full text

Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens by Özlem Yersal, Ufuk Eryilmaz, Hakan Akdam, Nezih Meydan, Sabri Barutca

“…Methods and Material. We enrolled 45 HER2-positive breast cancer patients who are on follow-up at least for six months after completion of adjuvant chemotherapy with trastuzumab, and cardiovascular risk matched 30 control volunteers. …”
Get full text

Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma by Martina Napolitano, Lucia Trudu, Enrica Martinelli, Chiara Santini, Massimo Dominici, Federica Bertolini

“…Conclusions This case confirms the potential efficacy of neratinib in HER2‐positive SDC and underlines the need to define the best therapeutic sequence and potential biomarkers for these rare patients.…”
Get full text

Relationship between the ultrasound features of different molecular subtypes of breast cancer and positive PD-1/PD-L1 expression by Ruiqian Yan, Haixia Li, Junxi Gao

“…Among 121 PD-L1-positive cases, many HER-2-positive and triple-negative cases presented as large masses (diameter ≥ 2 cm), while luminal B cases were more likely to show calcification. …”
Get full text